- Home
- FEDU vs NRSN Comparison
FEDU vs NRSN Comparison
Compare FEDU & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEDU
- NRSN
- Stock Information
- Founded
- FEDU 2007
- NRSN 2017
- Country
- FEDU China
- NRSN Israel
- Employees
- FEDU N/A
- NRSN N/A
- Industry
- FEDU
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- FEDU
- NRSN Health Care
- Exchange
- FEDU NYSE
- NRSN Nasdaq
- Market Cap
- FEDU 22.2M
- NRSN 17.8M
- IPO Year
- FEDU 2017
- NRSN 2021
- Fundamental
- Price
- FEDU $10.17
- NRSN $1.09
- Analyst Decision
- FEDU
- NRSN Hold
- Analyst Count
- FEDU 0
- NRSN 1
- Target Price
- FEDU N/A
- NRSN N/A
- AVG Volume (30 Days)
- FEDU 3.3K
- NRSN 159.3K
- Earning Date
- FEDU 12-20-2024
- NRSN 04-04-2025
- Dividend Yield
- FEDU 22.42%
- NRSN N/A
- EPS Growth
- FEDU N/A
- NRSN N/A
- EPS
- FEDU 0.12
- NRSN N/A
- Revenue
- FEDU $27,971,139.00
- NRSN N/A
- Revenue This Year
- FEDU N/A
- NRSN N/A
- Revenue Next Year
- FEDU N/A
- NRSN N/A
- P/E Ratio
- FEDU $85.33
- NRSN N/A
- Revenue Growth
- FEDU 141.14
- NRSN N/A
- 52 Week Low
- FEDU $7.41
- NRSN $0.51
- 52 Week High
- FEDU $22.70
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- FEDU 48.25
- NRSN 44.12
- Support Level
- FEDU $9.78
- NRSN $1.12
- Resistance Level
- FEDU $10.77
- NRSN $1.24
- Average True Range (ATR)
- FEDU 0.53
- NRSN 0.08
- MACD
- FEDU 0.04
- NRSN -0.01
- Stochastic Oscillator
- FEDU 49.43
- NRSN 13.57
About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)
Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.